Pharmacodynamics. Glucosamine is a substrate for the construction of articular cartilage and stimulates the regeneration of cartilage tissue. Glucosaminoglycans and proteoglycans are part of the complex matrix that makes up cartilage.
Glucosamine is a part of endogenous glucosaminoglycans of cartilage tissue, stimulates the production of proteoglycans and increases the absorption of sulfate by the articular cartilage.
Thus, glucosamine compensates for endogenous glucosamine deficiency. Participates in the biosynthesis of proteoglycans and hyaluronic acid, which counteracts the progression of degenerative processes in the joints, spine and surrounding soft tissues; stimulates the formation of chondroitinsulfuric acid, normalizes the deposition of calcium in bone tissue, helps to restore joint functions and the disappearance of pain.
Chondroitin sodium sulfate has a chondroprotective effect, stimulates the regeneration of cartilage tissue, exhibits an anti-inflammatory, analgesic effect. Chondroitin sodium sulfate affects phosphorus-calcium metabolism in cartilage tissue, is a high molecular weight mucopolysaccharide. The preparation slows down the resorption of bone tissue and reduces the loss of calcium, slows down the processes of degeneration of cartilage tissue. It prevents the compression of connective tissue, “lubricates” the articular surfaces and normalizes the production of joint fluid.
Pharmacokinetics. Glucosamine sulfate. The oral bioavailability of glucosamine is 25–26%. After distribution in tissues, Cmax is determined in the liver, kidneys and cartilage tissue. About 90% of the glucosamine that enters the body by the oral route is absorbed in the small intestine in the form of the glucosamine salt and from there it enters the liver through the portal bloodstream. A significant part of the absorbed glucosamine is metabolized in the liver. Decomposes to urea, water and carbon dioxide. About 30% of the dose taken persists for a long time in the connective tissue. It is excreted by the kidneys and in a very small amount is excreted in the feces.
Chondroitin sodium sulfate. After a single dose of chondroitin Cmax in the blood plasma is achieved after 3-4 hours, in the synovial fluid - after 4-5 hours. The concentration in the synovial fluid exceeds that in the blood plasma. The bioavailability of sodium chondroitin sulfate is 13-15%. Excreted by the kidneys within 24 hours.
Degenerative-dystrophic diseases of the joints and spine; primary and secondary osteoarthritis, osteochondrosis, humeroscapular periarthritis; fractures (to speed up the formation of callus).
The tablets are taken orally with a small amount of liquid.
During the first 3 weeks, 1 tablet should be used 3 times a day; in the following days - 1-2 tablets 2 times a day for 3 months. Repeat the course 2-3 times a year.
According to the doctor's prescription, the treatment may be longer.
Children. There is no experience of using the preparation in children, the use is not recommended.
Hypersensitivity to the components of the preparation, phenylketonuria, impaired liver or kidney function in the stage of decompensation, a tendency to bleeding. do not use if you are allergic to shellfish.
From the gastrointestinal tract: dyspepsia, nausea, vomiting, epigastric pain, diarrhea, constipation, bloating.
On the part of the skin and its structures: dermatitis, hair loss.
From the immune system: allergic reactions, including skin rashes, urticaria, flushing, eczema, pruritus, angioedema.
From the nervous system and sensory organs: headache, general weakness, drowsiness, insomnia, fatigue, dizziness, visual disturbances.
Others: edema.
All side effects disappear after stopping treatment.
Do not exceed the recommended dose.
At the beginning of treatment in patients with diabetes mellitus, it is advisable to control the level of glucose in the blood. Use only under medical supervision in patients with thrombophlebitis. Use with caution in patients with renal and hepatic impairment.
Use during pregnancy and lactation. Due to the fact that there are no clinical data on the efficacy and safety of the preparation during pregnancy and lactation, the preparation should not be used during this period.
The ability to influence the reaction rate when driving vehicles or other mechanisms. Studies on the effect of the preparation on the reaction rate when driving vehicles or other mechanisms have not been carried out. In case of drowsiness, fatigue, dizziness and / or visual impairment during the use of the preparation, refrain from driving or other mechanisms.
Increases the absorption of tetracyclines in the gastrointestinal tract, reduces the absorption of penicillins and chloramphenicol.
When using the preparation, the need for NSAIDs decreases.
The preparation can enhance the effect of anticoagulants, which requires monitoring of blood coagulation indicators while using it. May affect blood concentration of cyclosporine and warfarin.
Increased side effects are possible. in case of overdose, symptomatic treatment is recommended.
In its original packaging at a temperature not exceeding 25 ° C.
There are no reviews for this product.